Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer G. RovielloF. U. ConterN. Sobhani Review Article 11 June 2019 Pages: 669 - 677
Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer Annie RoysXing ChangDaiying Zuo Review Article 29 June 2019 Pages: 679 - 688
Current status of nanomedicine in the chemotherapy of breast cancer A. I. Fraguas-SánchezC. MartĂn-SabrosoA. I. Torres-Suárez Review Article 31 July 2019 Pages: 689 - 706
Population pharmacokinetics of trabectedin in adolescent patients with cancer Italo PoggesiBelén ValenzuelaJuan Jose Perez-Ruixo Original Article 08 July 2019 Pages: 707 - 717
Celastrol enhances TRAIL-induced apoptosis in human glioblastoma via the death receptor pathway Zhe ChaJianzhang ChengHuarong Yu Original Article 08 July 2019 Pages: 719 - 728
Species-specific optimization of PEG~SN-38 prodrug pharmacokinetics and antitumor effects in a triple-negative BRCA1-deficient xenograft Shaun D. FontaineByron HannDaniel. V. Santi Original Article 18 July 2019 Pages: 729 - 738
A simple ex vivo bioassay for 5-FU transport into healthy buccal mucosal cells Kathryn E. BurnsDaniel AllrightNuala A. Helsby Original Article 19 July 2019 Pages: 739 - 748
Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects Vassilios AslanisKenichi UmeharaBrian Gadbaw Original Article 19 July 2019 Pages: 749 - 757
A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer Cody J. PeerKeith T. SchmidtWilliam D. Figg Original Article 31 July 2019 Pages: 759 - 770
Identification of pharmacodynamic biomarkers and common molecular mechanisms of response to genotoxic agents in cancer cell lines Dong-Joon MinYingdong ZhaoRichard M. Simon Original Article 31 July 2019 Pages: 771 - 780
Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study Javier MunárrizGaspar ReynésIsabel Chirivella Original Article 31 July 2019 Pages: 781 - 789
A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24 Mansoor Raza MirzaTroels K. BergmannJohanna Mäenpää Original Article 02 August 2019 Pages: 791 - 798
A drug–drug interaction study to assess the potential effect of acid-reducing agent, lansoprazole, on quizartinib pharmacokinetics Jianke LiDenise TroneNatalie Cook Original Article Open access 05 August 2019 Pages: 799 - 807
Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma Mi Na KimSeung Min LeeSeong Gyu Hwang Original Article 05 August 2019 Pages: 809 - 817
A two centers study of postoperative adjuvant chemotherapy with S-1 versus SOX/XELOX regimens for gastric cancer after D2 resection: a cohort study Song ZhengYao ZhouYidan Lu Original Article 06 August 2019 Pages: 819 - 827
Pharmacokinetics and safety of erlotinib and its metabolite OSI-420 in infants and children with primary brain tumors Samuel J. ReddickOlivia CampagneClinton F. Stewart Original Article 07 August 2019 Pages: 829 - 838
Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial F. J. EstevaY. V. BaranauJ. Stebbing Original Article Open access 19 August 2019 Pages: 839 - 847
Pharmacokinetics of thiotepa in high-dose regimens for autologous hematopoietic stem cell transplant in Japanese patients with pediatric tumors or adult lymphoma Eisei KondoTakashi IkedaJunichi Hara Original Article Open access 19 August 2019 Pages: 849 - 860
FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer Mingyou XingJun WangSheng Zhou Original Article Open access 19 August 2019 Pages: 861 - 872
Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer Atsuto MouriKyoichi KairaHiroshi Kagamu Original Article 23 August 2019 Pages: 873 - 880
Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study Sacha I. RothschildDaniel BetticherMarkus Borner Original Article Open access 23 August 2019 Pages: 881 - 889
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia Ken OgasawaraSimon ZhouYan Li Original Article Open access 23 August 2019 Pages: 891 - 898
A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors Janice M. MehnertAmanda D. KaveneyMark N. Stein Original Article 28 August 2019 Pages: 899 - 907
A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial) Jeffrey Melson ClarkeGerard C. BlobeHerbert I. Hurwitz Clinical Trial Report Open access 23 August 2019 Pages: 909 - 917
A pilot study of first-line olaratumab, doxorubicin and ifosfamide in patients with metastatic soft tissue sarcoma Olga VornicovaNissim HaimGil Bar-Sela Short Communication 13 August 2019 Pages: 919 - 923